Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone

(2013) Beatrice Gaugler et al.   CYTOTHERAPY

Validation of a formula for predicting daily CD34+ cell collection by leukapheresis

(2012) Eric R. Rosenbaum et al.   CYTOTHERAPY

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial

(2012) N. Russell et al.   HAEMATOLOGICA

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

(2011) K Hübel et al.   BONE MARROW TRANSPLANTATION

Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: A simple method using day 1 CD34+ cell yield

(2011) Hien K. Duong et al.   JOURNAL OF CLINICAL APHERESIS

Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

(2011) Jie Li et al.   TRANSFUSION

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

(2010) Paul Shaughnessy et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization

(2010) L J Costa et al.   BONE MARROW TRANSPLANTATION

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

(2010) K Hübel et al.   BONE MARROW TRANSPLANTATION

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

(2010) Stefan Fruehauf et al.   CYTOTHERAPY

Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor

(2010) Isabel Taubert et al.   CYTOTHERAPY

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient

(2009) Patrick Stiff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation

(2009) Patrick Wuchter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF

(2009) S Nimmagadda et al.   BONE MARROW TRANSPLANTATION

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

(2009) M J Dugan et al.   BONE MARROW TRANSPLANTATION